Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Instagram Outage Disrupts Thousands of U.S. Users 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
ST. LOUIS, May 19, 2017 -- GeneriCo, LLC (GeneriCo), a global specialty generic drug company, today announced that the Patent Trial and Appeal Board (“PTAB”) of the U.S. Patent and Trademark Office ruled in favor of its petition for Inter Partes Review (“IPR”) of the Valeant Pharmaceuticals International, Inc. U.S. Patent 8,865,688 (the ‘688 Patent). The PTAB’s decision invalidates all of the disputed claims of the '688 Patent that previously provided Apriso® (extended-release capsules containing 0.375g mesalamine as a locally-acting aminosalicylate indicated for the maintenance of remission of ulcerative colitis in adults) FDA Orange Book exclusivity through May 1, 2030.
“Along with our IPR partner Flat Line Capital, LLC, we are pleased that the PTAB has decided to invalidate all the disputed claims of the ‘688 Patent,” said Daniel Thompson, GeneriCo President and CEO. “While more remains to be done, this is a significant step forward to lowering prescription drug costs for patients and healthcare providers in the U.S. system.”
Kevin Barnes, Principal of Flat Line Capital, LLC added, “We believe this successful IPR outcome further validates our leadership in pharmaceutical intellectual property disputes and the effectiveness of our platform.”
About GeneriCo, LLC
GeneriCo, LLC is a generic pharmaceutical company focused on developing and marketing niche, high barrier drugs in the United States. The Company employs a four-pillar collaboration business strategy capitalizing on management’s deep industry knowledge and experience to collaborate with partners on the discovery, formulation, development and manufacture of generic drugs. The Company expects its 1st internally-developed ANDA to be filed in 2017.
Contact: Daniel Thompson, President and CEO Phone Number: 1.314.330.0800 Email: [email protected] www.genericopharma.com
